Group Version of the UP-A in a Spanish Public Mental Health Setting.
Launched by UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA · Mar 24, 2025
Trial Information
Current as of April 22, 2025
Active, not recruiting
Keywords
ClinConnect Summary
Anxiety and depression are among the most prevalent mental health disorders in adolescents, with growing concerns about their increasing incidence. Studies indicate that emotional disorders often co-occur due to shared transdiagnostic factors, such as poor emotion regulation, high negative affect, and cognitive avoidance. Given these shared mechanisms, transdiagnostic treatments like the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) have been developed to improve adaptive emotion regulation and reduce avoidance behaviors. While the UP-A has ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Presenting a primary diagnosis of an emotional disorder with mild or moderate severity, including the following disorders based on DSM-5 categories: Depressive Disorders (Major Depressive Disorder and Persistent Depressive Disorder), Anxiety Disorders (Specific Phobia, Panic Disorder, Agoraphobia, Social Anxiety Disorder, Generalized Anxiety Disorder), Obsessive-Compulsive and Related Disorders (including Body Dysmorphic Disorder, Hoarding Disorder, Trichotillomania and Excoriation (Skin-Picking) Disorder), Trauma and Stressor-Related Disorders (Reactive Attachment Disorder, Post-Traumatic Stress Disorder, Acute Stress Disorder and Adjustment Disorders), Dissociative Disorders (Dissociative Identity Disorder, Depersonalization/Derealization Disorder) and Somatic Symptom and Related Disorders (Somatic Symptom Disorder and Illness Anxiety Disorder). Specified and unspecified disorders from the above categories were also included.
- • Being 11-18 years of age
- • Being proficient in Spanish
- • The adolescent being able to attend the treatment sessions
- • At least one of the adolescent's parents or legal guardians being able to attend the parents' treatment sessions
- • If the participant was taking psychiatric medication, the dose was required to remain stable for at least 1 month before the start of treatment and throughout it
- Exclusion Criteria:
- • Presenting self-harm or suicidal ideation in a moderate or severe degree
- • Presenting certain of the following clinical conditions (either as a main or comorbid diagnosis): Neurodevelopmental Disorders (Intellectual Disability or Autism Spectrum Disorder); Disruptive, Impulse-Control and Conduct Disorders; Eating Disorders; Psychotic Spectrum Disorders or psychotic-type symptoms,; Substance Abuse Disorders (excluding cannabis, coffee and/or nicotine); high severity Emotional Disorders; and Bipolar Disorders
- • The characteristics or severity of the symptoms presented by the adolescent requiring an individual intervention or one adapted to the specific clinical condition
- • Be receiving public or private psychological treatment during the UP-A program
- • Suffering from a serious medical illness that made the adolescent's participation in the treatment program unsustainable
- • The participant, or if under 16 years of age, his or her parents, having refused to sign the informed consent
Trial Officials
Paloma Chorot, Professor
Study Director
Universidad Nacional de Educación a Distancia
About Universidad Nacional De Educación A Distancia
The Universidad Nacional de Educación a Distancia (UNED) is a prominent Spanish institution dedicated to distance education and innovative learning methodologies. As a clinical trial sponsor, UNED leverages its extensive academic expertise and research capabilities to advance medical knowledge and improve healthcare outcomes. By fostering collaboration between interdisciplinary teams, UNED facilitates rigorous clinical research that adheres to the highest ethical standards and regulatory requirements, ultimately contributing to the development of effective therapeutic interventions and enhancing patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported